Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2952-2965

  Sathigari, Sateesh Kumar ^a   Ober, Courtney A ^b   Sanganwar, Ganesh P ^b   Gupta, Ram B ^b   Babu, R Jayachandra ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Dissolution rate; Nanotechnology; Particle size; Solid state; Supercritical fluids

Indexed keywords

DODECYL SULFATE SODIUM; DRUG SOLVENT; ITRACONAZOLE; POLOXAMER;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; CRYSTALLIZATION; DRUG FORMULATION; DRUG INTERACTION; DRUG SOLUBILITY; DRUG SYNTHESIS;

EID: 79955608012     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22524     Document Type: Article

References (59)

1. Amidon GL, Lennernaes H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
2. Rogers TL, Gillespie IB, Hitt JE, Fransen KL, Crowl CA, Tucker CJ, Kupperblatt GB, Becker JN, Wilson DL, Todd C, Broomall CF, Evans JC, Elder EJ. 2004. Development and Characterization of a scalable controlled precipitation process to enhance the dissolution of poorly water-soluble drugs. Pharm Res 21(11):2048-2057.
3. Rasenack N, Mueller BW. 2002. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res 19(12):1894-1900.
4. Jounela AJ, Pentikainen PJ, Sothmann A. 1975. Effect of particle size on the bioavailability of digoxin. Eur J Clin Pharmacol 8(5):365-370.
5. Liversidge GG, Cundy KC. 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125(1):91-97.
6. Vogt M, Kunath K, Dressman JB. 2008. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: Comparison with commercial preparations. Eur J Pharm Biopharm 68(2):283-288.
7. Brewster ME, Loftsson T, Estes KS, Lin JL, Fridriksdottir H, Bodor N. 1992. Effect of various cyclodextrins on solution stability and dissolution rate of doxorubicin hydrochloride. Int J Pharm 79(2-3):289-299.
8. Badr-Eldin SM, Elkheshen SA, Ghorab MM. 2008. Inclusion complexes of tadalafil with natural and chemically modified beta -cyclodextrins. I: Preparation and in-vitro evaluation. Eur J Pharm Biopharm 70(3):819-827.
9. Sathigari S, Chadha G, Lee YHP, Wright N, Parsons Daniel L, Rangari Vijay K, Fasina O, Babu RJ. 2009. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS Pharm Sci Tech 10(1):81-87.
10. Phillip Lee YH, Sathigari S, Jean Lin YJ, Ravis William R, Chadha G, Parsons Daniel L, Rangari Vijay K, Wright N, Babu RJ. 2009. Gefitinib-cyclodextrin inclusion complexes: Physico-chemical characterization and dissolution studies. Drug Dev Ind Pharm 35(9):1113-1120.
11. Joshi HN, Tejwani RW, Davidovich M, Sahasrabudhe VP, Jemal M, Bathala MS, Varia SA, Serajuddin ATM. 2004. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int J Pharm 269(1):251-258.
12. Dannenfelser R-M, He H, Joshi Y, Bateman S, Serajuddin ATM. 2004. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci 93(5):1165-1175
13. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni S. 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: A case study. Mol Pharm 5(6):981-993.
14. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. 2006. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: Generation of drug microparticles and drug-polymer solid dispersions. Int J Pharm 308(1-2):69-83.
15. Han H-K, Choi H-K. 2007. Improved absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm 65(1):99-103.
16. Gwak H-S, Choi J-S, Choi H-K. 2005. Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int J Pharm 297(1-2):156-161.
17. O'Connor KM, Corrigan OI. 2001. Comparison of the physicochemical properties of the N-(2-hydroxyethyl)pyrrolidine, diethylamine and sodium salt forms of diclofenac. Int J Pharm 222(2):281-293.
18. Balakrishnan A, Rege BD, Amidon GL, Polli JE. 2004. Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci 93(8):2064-2075.
19. Chavanpatil MD, Khdair A, Panyam J. 2007. Surfactant-polymer nanoparticles: A novel platform for sustained and enhanced cellular delivery of water-soluble molecules. Pharm Res 24(4):803-810.
20. Chiou WL, Chen S-J, Athanikar N. 1976. Enhancement of dissolution rates of poorly water-soluble drugs by crystallization in aqueous surfactant solutions. I: Sulfathiazole, prednisone, and chloramphenicol. J Pharm Sci 65(11):1702-1704.
21. Granero GE, Ramachandran C, Amidon GL. 2005. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev Ind Pharm 31(9):917-922.
22. Wong SM, Kellaway IW, Murdan S. 2006. Enhancement of the dissolution rate and oral absorption of a poorly water-soluble drug by formation of surfactant-containing microparticles. Int J Pharm 317(1):61-68.
23. Kawakami K, Miyoshi K, Ida Y. 2004. Solubilization behavior of poorly soluble drugs with combined use of Gelucire 44/14 and cosolvent. J Pharm Sci 93(6):1471-1479.
24. Viernstein H, Weiss-Greiler P, Wolschann P. 2003. Solubility enhancement of low soluble biologically active compounds-temperature and cosolvent dependent inclusion complexation. Int J Pharm 256(1-2):85-94.
25. Blagden N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 59(7):617-630.
26. Jung J, Perrut M. 2001. Particle design using supercritical fluids: Literature and patent survey. J Supercrit Fluids 20(3):179-219.
27. Loth H, Hemgesberg E. 1986. Properties and dissolution of drugs micronized by crystallization from supercritical gases. Int J Pharm 32(2-3):265-267.
28. Foster NR, Dehghani F, Charoenchaitrakool KM, Warwick B. 2003. Application of dense gas techniques for the production of fine particles. PharmSci 5(2): 32-38.
29. Jonghwi L. 2003. Drug nano and microparticles processed into solid dosage forms: Physical properties. J Pharm Sci 92(10):2057-2068.
30. Farinha A, Bica A, Tavares P. 2000. Improved bioavailability of a micronized megestrol acetate tablet formulation in humans. Drug Dev Ind Pharm 26(5):567-570.
31. Sitruk-Ware R, Bricaire C, De Lignieres B, Yaneva H, Mauvais-Jarvis P. 1987. Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications-A review. Contraception 36(4):373-402.
32. Barrett AM, Dehghani F, Foster NR. 2008. Increasing the dissolution rate of itraconazole processed by gas antisolvent techniques using polyethylene glycol as a carrier. Pharm Res 25(6):1274-1289.
33. Reverchon E, Della Porta G. 2001. Supercritical fluids-assisted micronization techniques. Low-impact routes for particle production. Pure Appl Chem 73(8):1293-1297.
34. Pasquali I, Bettini R, Giordano F. 2008. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev 60(3):399-410.
35. Lengsfeld CS, Delplanque JP, Barocas VH, Randolph TW. 2000. Mechanism governing microparticle morphology during precipitation by a compressed antisolvent: Atomization vs nucleation and growth. J Phys Chem B 104(12):2725-2735.
36. Reverchon E, Torino E, Dowy S, Braeuer A, Leipertz A. 2010. Interactions of phase equilibria, jet fluid dynamics and mass transfer during supercritical antisolvent micronization. Chem Eng J 156(2):446-458.
37. Perez de Diego Y, Pellikaan HC, Wubbolts FE, Witkamp GJ, Jansens PJ. 2005. Operating regimes and mechanism of particle formation during the precipitation of polymers using the PCA process. J Supercrit Fluids 35(2):147-156.
38. Sacha GA, Schmitt WJ, Nail SL. 2006. Identification of critical process variables affecting particle size following precipitation using a supercritical fluid. Pharm Dev Technol 11(2):187-194.
39. Sacha GA, Schmitt WJ, Nail SL. 2006. Identification of physical-chemical variables affecting particle size following precipitation using a supercritical fluid. Pharm Dev Technol 11(2):195-205.
40. Reverchon E, de Marco I, Torino E. 2007. Nanoparticles production by supercritical antisolvent precipitation: A general interpretation. J Supercrit Fluids 43(1):126-138.
41. Aguiar AJ, Zelmer JE, Kinkel AW. 1967. Deaggregation behavior of a relatively insoluble substituted benzoic acid and its sodium salt. J Pharm Sci 56(10):1243-1252.
42. Swanepoel E, Liebenberg W, de Villiers MM, Dekker TG. 2000. Dissolution properties of piroxicam powders and capsules as a function of particle size and the agglomeration of powders. Drug Dev Ind Pharm 26(10):1067-1076.
43. de Villiers MM. 1996. Influence of agglomeration of cohesive particles on the dissolution behavior of furosemide powder. Int J Pharm 136(1, 2):175-179.
44. Kale K, Hapgood K, Stewart P. 2009. Drug agglomeration and dissolution-What is the influence of powder mixing? Eur J Pharm Biopharm 72(1):156-164.
45. Harnby N. 2000. An engineering view of pharmaceutical powder mixing. Pharm Sci Technol Today 3(9):303-309.
46. Sanganwar GP, Sathigari S, Babu RJ, Gupta RB. 2010. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. Eur J Pharm Sci 39(1-3):164-174.
47. Hassan HA, Al-Marzouqi AH, Jobe B, Hamza AA, Ramadan GA. 2007. Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with beta-cyclodextrin using supercritical carbon dioxide. J Pharm Biomed Anal 45(2):243-250.
48. El Maghraby GM, Alomrani AH. 2009. Synergistic enhancement of itraconazole dissolution by ternary system formation with pluronic F68 and hydroxypropylmethylcellulose. Sci Pharm 77(2):401-417.
49. Liu D, Fei X, Wang S, Jiang T, Su D. 2006. Increasing solubility and dissolution rate of drugs via eutectic mixtures: Itraconazole-poloxamer 188 system. Asian J Pharm Sci (Hong Kong, China) 1(3-4):213-221.
50. Mellaerts R, Mols R, Jammaer JAG, Aerts CA, Annaert P, Van Humbeeck J, Van Den Mooter G, Augustijns P, Martens JA. 2008. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur J Pharm Biopharm 69(1):223-230.
51. Mellaerts R, Aerts A, Caremans TP, Vermant J, Van Den Mooter G, Martens JA, Augustijns P. Growth of itraconazole nanofibers in supersaturated simulated intestinal fluid. Mol Pharm 7(3):905-913.
52. Wulsten E, Kiekens F, van Dycke F, Voorspoels J, Lee G. 2009. Levitated single-droplet drying: Case study with itraconazole dried in binary organic solvent mixtures. Int J Pharm 378(1-2):116-121.
53. Higuchi T, Connors KA. 1965. Phase-solubility techniques. Adv Anal Chem Instr 4:117-212.
54. Shekunov BY, Chattopadhyay P, Tong HHY, Chow AHL. 2007. Particle size analysis in pharmaceutics: Principles, methods and applications. Pharm Res 24(2):203-227.
55. Kim M-S, Lee S, Park J-S, Woo J-S, Hwang S-J. 2007. Micronization of cilostazol using supercritical antisolvent (SAS) process: Effect of process parameters. Powder Technol 177(2):64-70.
56. Chattopadhyay P, Gupta RB. 2002. Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChE J 48(2):235-244.
57. Sanganwar GP, Gupta RB. 2008. Enhancement of shelf life and handling properties of drug nanoparticles: Nanoscale mixing of itraconazole with silica. Ind Eng Chem Res 47(14):4717-4725.
58. Sinswat P, Gao X, Yacaman MJ, Williams RO, Johnston KP. 2005. Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution. Int J Pharm 302(1-2):113-124.
59. Noyes AA, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19(12):930-934.